Study guide
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS)
Veterinary Technician Specialist in Emergency and Critical Care VTS ECC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, Triage & Point-of-Care Assessment
1.1 AVECCTN Examination Structure, Blueprint & Credentialing 1.2 Emergency Triage Systems, Primary Survey & Capsule Diagnostics 1.3 Point-of-Care Ultrasound (POCUS / TFAST / AFAST / VetBLUE) & Rapid Interventions
2 Chapter 2: Cardiovascular Emergencies & RECOVER CPR
2.1 RECOVER Guidelines: Basic Life Support (BLS) & Resuscitation Dynamics 2.2 Advanced Life Support (ALS): Emergency Pharmacopeia, Reversals & Defibrillation 2.3 Electrocardiogram (ECG) Interpretation & Antiarrhythmic Therapy 2.4 Congestive Heart Failure, Cardiac Tamponade & Feline Aortic Thromboembolism
3 Chapter 3: Fluid Therapy, Shock Resuscitation & Acid-Base Balance
3.1 Pathophysiology, Stages & Classification of Shock 3.2 Fluid Dynamics, Crystalloids, Colloids & Hypertonic Resuscitation 3.3 Electrolyte Disorders: Potassium, Sodium, Calcium & Phosphorus 3.4 Arterial & Venous Blood Gas Analysis & Acid-Base Disorders
4 Chapter 4: Respiratory Emergencies & Mechanical Ventilation
4.1 Upper Airway Obstruction: BOAS, Laryngeal Paralysis & Tracheal Collapse 4.2 Lower Airway, Pulmonary Parenchymal & Vascular Emergencies: Asthma, Contusions & ARDS 4.3 Pleural Space Disease, Emergency Thoracocentesis & Chest Tube Management 4.4 Oxygen Delivery Modalities, Capnography & Mechanical Ventilation Basics
5 Chapter 5: Gastrointestinal & Hepatic Emergencies
5.1 Gastric Dilatation-Volvulus (GDV): Resuscitation, Decompression & Critical Nursing 5.2 Acute Abdomen, Septic Peritonitis & Canine Parvoviral Enteritis 5.3 Acute Pancreatitis, Acute Hemorrhagic Diarrhea Syndrome & Mesenteric Volvulus 5.4 Acute Hepatic Failure, Hepatic Encephalopathy & Biliary Emergencies
6 Chapter 6: Anesthesia, Analgesia & Constant Rate Infusions
6.1 Emergency Anesthesia Protocols & High-Risk Patient Stabilization 6.2 Multimodal Analgesia, Pain Scoring Scales & Local/Regional Anesthesia 6.3 Constant Rate Infusions (CRIs): Formulations, Calculations & Monitoring 6.4 Anesthetic Complications: Hypotension, Hypothermia & Emergency Interventions
7 Chapter 7: Renal & Urinary Emergencies
7.1 Acute Kidney Injury (AKI): Pathophysiology, IRIS Staging & Renal Replacement Therapy 7.2 Feline Urethral Obstruction: Deobstruction, Electrolyte Crises & Post-Obstructive Diuresis 7.3 Uroabdomen & Lower Urinary Tract Trauma: Diagnosis & Resuscitation
8 Chapter 8: Hemolymphatic, Transfusion Medicine & Sepsis/SIRS
8.1 Transfusion Medicine: Blood Typing, Crossmatching & Component Therapy 8.2 Immune-Mediated Hemolytic Anemia (IMHA) & Immune-Mediated Thrombocytopenia (IMTP) 8.3 Sepsis, Systemic Inflammatory Response Syndrome (SIRS) & DIC 8.4 Oncologic Emergencies: Tumor Lysis Syndrome, Bleeding Masses & Hypercalcemia
9 Chapter 9: Environmental, Toxicological, Ophthalmic & Exotic Species Emergencies
9.1 Heatstroke, Severe Hypothermia & Thermal Burn Management 9.2 Envenomation Syndromes & Acute Anaphylaxis Management 9.3 Common Small Animal Toxicities: Chocolate, Xylitol, NSAIDs & Rodenticides 9.4 Neurotoxins, Ethylene Glycol, Plant Toxins & Extracorporeal Therapies 9.5 Ophthalmologic Emergencies: Proptosis, Acute Glaucoma, Corneal Perforation & Chemical Injury 9.6 Emergency Care of Exotic Companion Species: Rabbits, Rodents, Ferrets, Birds & Reptiles
10 Chapter 10: Neurological Emergencies
10.1 Status Epilepticus & Cluster Seizures: Emergency Protocols & Refractory Therapy 10.2 Traumatic Brain Injury (TBI), Intracranial Pressure (ICP) & Modified Glasgow Coma Scale 10.3 Acute Spinal Cord Emergencies: Intervertebral Disc Disease (IVDD) & Neuro-Localization
11 Chapter 11: Endocrine & Metabolic Crises
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Acute Adrenocortical Crisis (Addisonian Crisis) & Hypoadrenocorticism 11.3 Thyroid Storm, Feline Hyperthyroid Crises & Severe Hypoglycemia
12 Chapter 12: Reproductive & Musculoskeletal Emergencies
12.1 Reproductive Emergencies: Dystocia, Pyometra & Puerperal Hypocalcemia 12.2 Musculoskeletal Trauma: Open Fractures, Luxations, Splints & Compartment Syndrome 12.3 Rhabdomyolysis, Crush Injury & Polytrauma Damage Control Resuscitation
13 Chapter 13: Advanced Critical Care Monitoring, Vascular Access & The Rule of 20
13.1 Central Venous Catheterization, Arterial Lines & Intraosseous Access 13.2 Hemodynamic Monitoring: Invasive vs. Non-Invasive Blood Pressure, CVP & Cardiac Output 13.3 Kirby's Rule of 20: Comprehensive Daily Critical Patient Evaluation Checklist
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS)
Key Takeaways Explain This Topic AI
Diabetic Ketoacidosis (DKA) is caused by a severe absolute or relative insulin deficiency coupled with marked elevations in counter-regulatory stress hormones (glucagon, cortisol, epinephrine, growth hormone), which drives uninhibited peripheral lipolysis and hepatic ketogenesis.
The classic diagnostic quartet for DKA consists of hyperglycemia (>300-400 mg/dL), glucosuria, ketonemia/ketonuria, and high anion gap metabolic acidosis (pH <7.30, HCO3- <15 mEq/L); standard urine dipstick nitroprusside reagents detect acetoacetate and acetone, but fail to detect beta-hydroxybutyrate, the primary circulating ketone in acute DKA.
Hyperosmolar Hyperglycemic State (HHS) presents with profound hyperglycemia (>600-1000 mg/dL) and severe hyperosmolality (>350 mOsm/kg) with minimal or absent ketoacidosis because residual trace insulin inhibits lipolysis while failing to promote peripheral glucose uptake.
Phase 1 resuscitation mandates aggressive intravascular volume restoration using balanced isotonic crystalloids over the first 2-4 hours, during which insulin must be strictly withheld to prevent sudden intracellular osmotic fluid shifts, vascular collapse, and precipitous hypokalemia.
Low-dose regular insulin therapy (0.05-0.1 U/kg/hr CRI or 0.1 U/kg/hr IM) must decrease blood glucose gradually at 50-75 mg/dL/hr to avoid cerebral edema, with 2.5-5.0% dextrose added to fluids once glucose reaches 200-250 mg/dL to maintain insulin delivery until ketoacidosis resolves.
Last updated: August 2026
Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS)
VTS Critical Concept: Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) represent life-threatening decompensations of diabetes mellitus. Successful management hinges on a phased resuscitation strategy: volume expansion first, electrolyte repletion second, and insulin therapy third . Administering insulin prematurely prior to fluid and potassium stabilization triggers catastrophic intravascular volume collapse, refractory hypokalemia, and cerebral edema.
1. Pathophysiology of DKA & Ketogenesis
Diabetic Ketoacidosis develops from a synergistic physiological failure: profound absolute or relative insulin deficiency accompanied by an excess of counter-regulatory stress hormones (glucagon, cortisol, epinephrine, and growth hormone). This hormonal imbalance creates an extreme catabolic state. [ Absolute / Relative Insulin Deficiency + Excess Stress Hormones (Glucagon, Cortisol, Epi) ]
- │
- ┌───────────────────────────┴───────────────────────────┐
- ▼ ▼
- [ Uninhibited Lipolysis ] [ Hepatic Gluconeogenesis & ]
- Hormone-Sensitive Lipase activated [ Impaired Peripheral Uptake ]
- │ │
- ▼ ▼
- [ Free Fatty Acids (FFAs) Mobilized ] [ Severe Hyperglycemia ]
- Carnitine Palmitoyltransferase-1 (CPT-1) activated │
- │ ▼
- ▼ [ Glucosuria & Osmotic Diuresis ]
- [ Hepatic Mitochondrial Beta-Oxidation ] Profound Dehydration & Shock
- Acetoacetyl-CoA ──► Acetoacetate (AcAc) │
- │ │
- ▼ (Redox Shift: High NADH/NAD+) │
- [ Beta-Hydroxybutyrate (β-OHB) Predominance ] │
- │ │
- └───────────────────────────┬───────────────────────────┘
- ▼
- [ High Anion Gap Metabolic Acidosis + Severe Electrolyte Wasting ]
- The Ketogenic Pathway & Redox Shift
Lipolysis Activation: In the absence of insulin's inhibitory signal, adipose hormone-sensitive lipase becomes hyperactive, hydrolyzing triglycerides into glycerol and large quantities of non-esterified Free Fatty Acids (FFAs) .
Hepatic Carnitine Palmitoyltransferase-1 (CPT-1): Elevated glucagon levels reduce hepatic malonyl-CoA concentrations, disinhibiting CPT-1. This allows rapid transport of FFAs into hepatic mitochondria for accelerated β \beta β -oxidation.
Ketone Body Formation: Overwhelming acetyl-CoA production exceeds the capacity of the citric acid (Krebs) cycle. Excess acetyl-CoA is shunted into ketogenesis, forming acetoacetate (AcAc) , which spontaneously decarboxylates into acetone or is enzymatically reduced to β \beta β -hydroxybutyrate ( β \beta β -OHB) via β \beta β -hydroxybutyrate dehydrogenase.
The Mitochondrial Redox State: In severe shock, tissue hypoxia and hepatic hypoperfusion cause a high mitochondrial [ NADH ] / [ NAD + ] [\text{NADH}]/[\text{NAD}^+] [ NADH ] / [ NAD + ] ratio. This drives the equilibrium strongly toward β \beta β -hydroxybutyrate , making β \beta β -OHB the overwhelmingly dominant circulating ketone in acute DKA (often reaching a β -OHB : AcAc \beta\text{-OHB} : \text{AcAc} β -OHB : AcAc ratio of 3 : 1 3:1 3 : 1 to > 10 : 1 >10:1 > 10 : 1 ).
High Anion Gap Metabolic Acidosis
Acetoacetic acid and β \beta β -hydroxybutyric acid are strong organic acids that fully dissociate at physiological pH, releasing free hydrogen ions ( H + H^+ H + ) and ketone anions. Circulating bicarbonate ( H C O 3 − HCO_3^- H C O 3 − ) buffers the excess H + H^+ H + , causing severe metabolic acidemia and an elevated Anion Gap (AG) : Anion Gap (AG) = ( [ Na + ] + [ K + ] ) − ( [ Cl − ] + [ HCO 3 − ] ) \text{Anion Gap (AG)} = ([\text{Na}^+] + [\text{K}^+]) - ([\text{Cl}^-] + [\text{HCO}_3^-]) Anion Gap (AG) = ([ Na + ] + [ K + ]) − ([ Cl − ] + [ HCO 3 − ])
(Normal canine/feline AG: 12 − 24 mEq/L 12-24\text{ mEq/L} 12 − 24 mEq/L ; in acute DKA, AG frequently exceeds 28 − 35 mEq/L 28-35\text{ mEq/L} 28 − 35 mEq/L due to unmeasured ketoacids).
2. Clinical Presentation & The Diagnostic Quartet
Patients with DKA frequently have an underlying concurrent trigger that increased counter-regulatory hormones (e.g., acute pancreatitis, severe bacterial urinary tract infection, pyometra, bacterial pneumonia, Cushing's disease, or chronic kidney disease).
Clinical Signs & Physical Examination Findings
History: Polyuria, polydipsia (PU/PD), progressive weight loss, polyphagia progressing rapidly to complete anorexia, acute vomiting, lethargy, and mental dullness.
Kussmaul Respiration: Deep, rapid, unlabored hyperventilation without wheezes or crackles. This represents physiological respiratory compensation (blowing off arterial C O 2 CO_2 C O 2 to raise blood pH) in response to severe metabolic ketoacidosis.
Acetone Breath Odor: A distinct sweet, fruity, or solvent-like breath odor caused by exhaled volatile acetone.
Dehydration & Hypovolemic Shock: Dry, tacky oral mucous membranes, prolonged skin turgor, sunken orbits (enophthalmos), weak peripheral pulses, and cool extremities secondary to severe osmotic diuresis and gastrointestinal fluid loss.
The Diagnostic Quartet for DKA
Diagnostic Pillar Diagnostic Threshold Clinical & Pathophysiological Nuance
1. Hyperglycemia Blood glucose > 300 − 400 mg/dL >300-400\text{ mg/dL} > 300 − 400 mg/dL ( > 16.7 − 22.2 mmol/L >16.7-22.2\text{ mmol/L} > 16.7 − 22.2 mmol/L ) Severe elevation exceeding renal tubular resorptive capacity (renal threshold: ∼ 180 mg/dL \sim 180\text{ mg/dL} ∼ 180 mg/dL dogs; ∼ 280 mg/dL \sim 280\text{ mg/dL} ∼ 280 mg/dL cats)
2. Glucosuria 3 + 3+ 3 + to 4 + 4+ 4 + on urine dipstick Direct consequence of filtered glucose overwhelming proximal tubular sodium-glucose cotransporters (SGLT2)
3. Ketonemia / Ketonuria Elevated blood β \beta β -OHB ( > 2.5 − 3.0 mmol/L >2.5-3.0\text{ mmol/L} > 2.5 − 3.0 mmol/L ) or urine ketones Demonstrates active hepatic ketogenesis; blood measurement is vastly superior to urine test strips
4. Metabolic Acidosis Venous/Arterial pH < 7.30 \text{pH} < 7.30 pH < 7.30 , [ HCO 3 − ] < 15 mEq/L [\text{HCO}_3^-] < 15\text{ mEq/L} [ HCO 3 − ] < 15 mEq/L , High AG High anion gap metabolic acidosis secondary to organic ketoacid accumulation and hyperlactatemia
The Urine Dipstick Nitroprusside Pitfall
Standard urine test strips utilize the nitroprusside reaction , which reacts strongly with acetoacetate and weakly with acetone , but possesses ZERO reactivity with β \beta β -hydroxybutyrate .
Early False Negatives: In patients with severe shock and high [ NADH ] / [ NAD + ] [\text{NADH}]/[\text{NAD}^+] [ NADH ] / [ NAD + ] redox states, almost all circulating ketones exist as β \beta β -OHB. A urine dipstick may read trace or negative for ketones despite life-threatening ketoacidosis.
The Paradoxical 'Worsening' on Dipstick: As resuscitation restores tissue perfusion and oxygen delivery, the [ NADH ] / [ NAD + ] [\text{NADH}]/[\text{NAD}^+] [ NADH ] / [ NAD + ] ratio normalizes. β \beta β -OHB is oxidized back into acetoacetate. Consequently, urine dipsticks may turn strongly positive ( 4 + 4+ 4 + ) after clinical improvement has begun. Point-of-care blood ketone meters directly measuring blood β \beta β -OHB are the gold standard.
3. Hyperosmolar Hyperglycemic State (HHS / HHNK)
Hyperosmolar Hyperglycemic State (HHS) —formerly termed Hyperosmolar Hyperglycemic Non-Ketotic Syndrome (HHNK)—is an extreme endocrine crisis characterized by massive hyperglycemia and hyperosmolality without profound ketoacidosis.
Pathophysiological Differences: DKA vs. HHS
- Clinical Parameter Diabetic Ketoacidosis (DKA) Hyperosmolar Hyperglycemic State (HHS)
- Insulin Availability Severe absolute/relative deficiency Trace residual endogenous insulin present
Lipolysis & Ketogenesis Uninhibited; massive β \beta β -OHB and AcAc Inhibited by trace insulin; minimal/absent ketones
Blood Glucose Typically 300 − 600 mg/dL 300-600\text{ mg/dL} 300 − 600 mg/dL Extreme: > 600 − 1200 + mg/dL >600-1200+\text{ mg/dL} > 600 − 1200 + mg/dL ( > 33.3 − 66.6 mmol/L >33.3-66.6\text{ mmol/L} > 33.3 − 66.6 mmol/L )
Effective Osmolality Mild-to-moderate ( < 320 − 330 mOsm/kg <320-330\text{ mOsm/kg} < 320 − 330 mOsm/kg ) Profound: > 350 mOsm/kg >350\text{ mOsm/kg} > 350 mOsm/kg (often > 380 mOsm/kg >380\text{ mOsm/kg} > 380 mOsm/kg )
Acid-Base Status Severe metabolic acidosis ( pH < 7.20 \text{pH} < 7.20 pH < 7.20 ) Mild/Normal ( pH > 7.30 \text{pH} > 7.30 pH > 7.30 , [ HCO 3 − ] > 18 mEq/L [\text{HCO}_3^-] > 18\text{ mEq/L} [ HCO 3 − ] > 18 mEq/L )
Dehydration & Mentation Moderate-to-severe ( 6 − 10 % 6-10\% 6 − 10% ); alert to dull Severe to extreme ( 10 − 15 % 10-15\% 10 − 15% ); profound stupor/coma
Prognosis & Mortality Fair to good ( 70 − 80 % 70-80\% 70 − 80% hospital discharge) Guarded to poor ( 30 − 40 % 30-40\% 30 − 40% survival rate)
Calculated Effective Serum Osmolality
Glucose is an effective osmole that cannot freely cross cell membranes in the absence of insulin. Osmolality draws water from the intracellular into the extracellular space, causing severe intracellular neuronal dehydration: Effective Osmolality (mOsm/kg) = 2 × [ Na + (mEq/L) ] + Blood Glucose (mg/dL) 18 \text{Effective Osmolality (mOsm/kg)} = 2 \times [\text{Na}^+\text{ (mEq/L)}] + \frac{\text{Blood Glucose (mg/dL)}}{18} Effective Osmolality (mOsm/kg) = 2 × [ Na + (mEq/L) ] + 18 Blood Glucose (mg/dL) Effective Osmolality (SI Units) = 2 × [ Na + (mmol/L) ] + Blood Glucose (mmol/L) \text{Effective Osmolality (SI Units)} = 2 \times [\text{Na}^+\text{ (mmol/L)}] + \text{Blood Glucose (mmol/L)} Effective Osmolality (SI Units) = 2 × [ Na + (mmol/L) ] + Blood Glucose (mmol/L)
Loading diagram... Emergency Multi-Phase DKA Resuscitation Pathway
4. Emergency Multi-Phase Resuscitation Protocol
Resuscitation of DKA must proceed in a strict, stepwise chronological sequence. Attempting to correct hyperglycemia before restoring intravascular volume and electrolyte reserves is the leading cause of iatrogenic mortality.
Phase 1: Intravascular Volume Expansion (Hours 0 to 4)
Fluid Selection: Balanced isotonic crystalloids (Plasmalyte-148, Normosol-R, or Lactated Ringer's Solution). If severe hyponatremia is present, 0.9 % NaCl 0.9\%\text{ NaCl} 0.9% NaCl may be utilized.
Fluid Deficit Calculation: Deficit Volume (mL) = Body Weight (kg) × % Dehydration × 1000 \text{Deficit Volume (mL)} = \text{Body Weight (kg)} \times \%\text{ Dehydration} \times 1000 Deficit Volume (mL) = Body Weight (kg) × % Dehydration × 1000 Administer initial shock aliquots ( 10 − 20 mL/kg 10-20\text{ mL/kg} 10 − 20 mL/kg over 15 − 30 min 15-30\text{ min} 15 − 30 min in dogs; 5 − 10 mL/kg 5-10\text{ mL/kg} 5 − 10 mL/kg in cats) if hypovolemic shock is present. Replace the calculated deficit plus ongoing losses and maintenance over 24 − 48 hours 24-48\text{ hours} 24 − 48 hours .
CRITICAL RULE: Withhold Insulin During Phase 1:
Prevention of Vascular Collapse: Intravascular volume is partially sustained by high serum hyperosmolality pulling fluid from the intracellular space. Administering insulin drives glucose into cells; water rapidly follows glucose via osmosis, causing catastrophic intravascular dehydration, acute hypotension, and cardiac arrest.
Hypokalemia Prevention: Insulin drives extracellular potassium into cells. Administering insulin before establishing baseline potassium and initiating replacement precipitates lethal cardiac arrhythmias.
Phase 2: Electrolyte Repletion (Potassium & Phosphate)
Total body stores of potassium, phosphate, and magnesium are profoundly depleted in DKA due to prolonged osmotic diuresis, anorexia, and vomiting. However, initial serum bloodwork may show normal or high potassium due to extracellular shifts driven by acidemia and lack of insulin.
Potassium Supplementation Guidelines
Supplement potassium in IV fluids as soon as serum [ K + ] < 5.0 mEq/L [\text{K}^+] < 5.0\text{ mEq/L} [ K + ] < 5.0 mEq/L and adequate urine output is confirmed. Never exceed the maximum safe peripheral IV potassium infusion rate of 0.5 mEq/kg/hr 0.5\text{ mEq/kg/hr} 0.5 mEq/kg/hr .
Serum Potassium Level ( [ K + ] [\text{K}^+] [ K + ] ) Potassium Added per Liter of IV Fluids Maximum Safe Fluid Rate ( 0.5 mEq/kg/hr 0.5\text{ mEq/kg/hr} 0.5 mEq/kg/hr )
> 5.0 mEq/L >5.0\text{ mEq/L} > 5.0 mEq/L No potassium added initially Monitor serially q2-4h
4.0 − 5.0 mEq/L 4.0 - 5.0\text{ mEq/L} 4.0 − 5.0 mEq/L 20 mEq KCl (or KPO 4 ) / L 20\text{ mEq KCl (or }\text{KPO}_4\text{)} / \text{L} 20 mEq KCl (or KPO 4 ) / L 25 mL/kg/hr 25\text{ mL/kg/hr} 25 mL/kg/hr
3.5 − 3.9 mEq/L 3.5 - 3.9\text{ mEq/L} 3.5 − 3.9 mEq/L 30 mEq / L 30\text{ mEq / L} 30 mEq / L 16.7 mL/kg/hr 16.7\text{ mL/kg/hr} 16.7 mL/kg/hr
3.0 − 3.4 mEq/L 3.0 - 3.4\text{ mEq/L} 3.0 − 3.4 mEq/L 40 mEq / L 40\text{ mEq / L} 40 mEq / L 12.5 mL/kg/hr 12.5\text{ mL/kg/hr} 12.5 mL/kg/hr
2.5 − 2.9 mEq/L 2.5 - 2.9\text{ mEq/L} 2.5 − 2.9 mEq/L 60 mEq / L 60\text{ mEq / L} 60 mEq / L 8.3 mL/kg/hr 8.3\text{ mL/kg/hr} 8.3 mL/kg/hr
< 2.5 mEq/L <2.5\text{ mEq/L} < 2.5 mEq/L 80 mEq / L 80\text{ mEq / L} 80 mEq / L 6.25 mL/kg/hr 6.25\text{ mL/kg/hr} 6.25 mL/kg/hr
Phosphate Repletion & Acute Hemolysis
Insulin therapy drives inorganic phosphorus into cells for glucose phosphorylation.
Severe hypophosphatemia ( [ PO 4 − ] < 1.5 mg/dL [\text{PO}_4^-] < 1.5\text{ mg/dL} [ PO 4 − ] < 1.5 mg/dL or < 0.48 mmol/L <0.48\text{ mmol/L} < 0.48 mmol/L ) depletes erythrocyte adenosine triphosphate (ATP) and 2,3-diphosphoglycerate (2,3-DPG), causing red blood cell membrane rigidity, Heinz body formation, and severe, life-threatening acute intravascular hemolytic anemia , alongside diaphragmatic muscle weakness and respiratory arrest.
Treatment: Replete 33 − 50 % 33-50\% 33 − 50% of calculated potassium requirements as Potassium Phosphate ( KPO 4 \text{KPO}_4 KPO 4 ) , with the remainder given as Potassium Chloride ( KCl \text{KCl} KCl ). Administer KPO 4 \text{KPO}_4 KPO 4 at 0.01 − 0.03 mmol/kg/hr 0.01-0.03\text{ mmol/kg/hr} 0.01 − 0.03 mmol/kg/hr .
Phase 3: Regular Insulin Therapy & Dextrose Infusion
Initiate insulin therapy 2 − 4 hours 2-4\text{ hours} 2 − 4 hours after initiating fluid resuscitation , once hypovolemia has resolved and serum potassium is ≥ 3.5 − 4.0 mEq/L \ge 3.5-4.0\text{ mEq/L} ≥ 3.5 − 4.0 mEq/L .
Insulin Protocols
Low-Dose Regular Insulin CRI (Preferred): Mix regular insulin (Humulin R, Novolin R) in 0.9 % NaCl 0.9\%\text{ NaCl} 0.9% NaCl (e.g., 2.2 U/kg 2.2\text{ U/kg} 2.2 U/kg in 250 mL 250\text{ mL} 250 mL saline, where 1 mL/hr = 0.01 U/kg/hr 1\text{ mL/hr} = 0.01\text{ U/kg/hr} 1 mL/hr = 0.01 U/kg/hr ). Note: Flush the first 50 mL 50\text{ mL} 50 mL through the IV administration set and discard, as insulin binds to plastic tubing surfaces. Initiate CRI at 0.05 − 0.1 U/kg/hr 0.05-0.1\text{ U/kg/hr} 0.05 − 0.1 U/kg/hr .
Intermittent Hourly Low-Dose IM Protocol: Administer an initial loading dose of Regular Insulin at 0.2 U/kg IM 0.2\text{ U/kg IM} 0.2 U/kg IM , followed by 0.1 U/kg IM q1h 0.1\text{ U/kg IM q1h} 0.1 U/kg IM q1h , monitoring blood glucose hourly.
Safe Rate of Glucose Reduction
Target Decline: Reduce blood glucose by 50 − 75 mg/dL/hr 50-75\text{ mg/dL/hr} 50 − 75 mg/dL/hr ( 2.8 − 4.2 mmol/L/hr 2.8-4.2\text{ mmol/L/hr} 2.8 − 4.2 mmol/L/hr ).
Danger of Rapid Drop: Dropping blood glucose faster than 75 − 100 mg/dL/hr 75-100\text{ mg/dL/hr} 75 − 100 mg/dL/hr creates a steep osmotic gradient between the rapidly hypotonic extracellular fluid and the brain (which retains idiogenic osmoles), triggering severe cerebral edema, stupor, coma, and herniation .
Adding Dextrose to Fluids (The 200-250 mg/dL Threshold)
When blood glucose declines to 200 − 250 mg/dL 200-250\text{ mg/dL} 200 − 250 mg/dL ( 11.1 − 13.9 mmol/L 11.1-13.9\text{ mmol/L} 11.1 − 13.9 mmol/L ), DO NOT STOP THE INSULIN .
Insulin is required to shut down hepatic ketogenesis, stimulate fatty acid synthesis, and clear circulating ketoacids. Stopping insulin allows ketogenesis to resume immediately.
Action: Add dextrose to the IV crystalloids to create a 2.5 % 2.5\% 2.5% to 5.0 % 5.0\% 5.0% dextrose solution (e.g., add 50 − 100 mL 50-100\text{ mL} 50 − 100 mL of 50 % 50\% 50% dextrose to a 1 L 1\text{ L} 1 L fluid bag) and decrease the insulin CRI to 0.025 − 0.05 U/kg/hr 0.025-0.05\text{ U/kg/hr} 0.025 − 0.05 U/kg/hr . Titrate dextrose infusion rates to maintain blood glucose between 150 − 250 mg/dL 150-250\text{ mg/dL} 150 − 250 mg/dL until ketonemia clears, venous pH exceeds 7.30 7.30 7.30 , [ HCO 3 − ] > 18 mEq/L [\text{HCO}_3^-] > 18\text{ mEq/L} [ HCO 3 − ] > 18 mEq/L , and the patient resumes voluntary eating.